AbbVie Expected To Ditch Abicipar After US FDA Setback
Executive Summary
With a complete response letter for wet AMD drug abicipar, AbbVie is expected to move on from the drug acquired with Allergan. Molecular Partners now seems inclined to focus on IO, virology.